The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Evidence That Nonsteroidal Anti-inflammatory Drugs Decrease Amyloid β42 Production by Direct Modulation of γ-Secretase Activity
Open accessAbstract
Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a lower risk of developing Alzheimer's disease. Recent evidence indicates that some NSAIDs specifically inhibit secretion of the amyloidogenic A beta 42 peptide in cultured cells and mouse models of Alzheimer's disease. The reduction of A beta 42 peptides is not mediated by inhibition of cyclooxygenases (COX) but the molecular mechanism underlying this novel activity of NSAIDs has not been further defined. We now demonstrate that NSAIDs efficiently reduce the intracellular pool of A beta 42 in cell-based studies and selectively decrease A beta 42 production in a cell-free assay of gamma-secretase activity. Moreover, we find that presenilin-1 (PS1) mutations, which affect gamma-secretase activity, differentially modulate the cellular A beta 42 response to NSAID treatment. Overexpression of the PS1-M146L mutation enhances the cellular drug response to A beta 42 lowering NSAIDs as compared with cells expressing wild-type PS1. In contrast, expression of the PS1-Delta Exon9 mutation strongly diminishes the A beta 42 response, showing that PS1 mutations can modulate the cellular drug response to NSAID treatment both positively and negatively. Enhancement of the NSAID drug response was also observed with overexpression of the APP V717F mutation but not with Swedish mutant APP, which affects beta-secretase cleavage. In sum, these results strongly suggest that NSAIDs represent a founding group of compounds that lower A beta 42 production by direct modulation of gamma-secretase activity or its substrate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., et al. (1999) · Nature · doi:10.1038/19083 · Cited by 2,100
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Suzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T. E., & Younkin, S. G. (1994) · Science · doi:10.1126/science.8191290 · Cited by 1,471
Self-citationThun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388
Self-citationMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110
PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs
He, T.-C., Chan, T. A., Vogelstein, B., & Kinzler, K. W. (1999) · Cell · doi:10.1016/s0092-8674(00)81664-5 · Cited by 1,085
Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and βAPP processing
Yu, G., Nishimura, M., Arawaka, S., Levitan, D., Zhang, L., Tandon, A., Song, Y.-Q., Rogaeva, E., Chen, F., Kawarai, T., et al. (2000) · Nature · doi:10.1038/35024009 · Cited by 911
Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease
Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W., Teter, B., Tran, T., Ubeda, O., Ashe, K. H., Frautschy, S. A., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05709.2000 · Cited by 884
Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1
Li, Y.-M., Xu, M., Lai, M.-T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvelil, J. G., et al. (2000) · Nature · doi:10.1038/35015085 · Cited by 866
γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase
Ni, C.-Y., Murphy, M. P., Golde, T. E., & Carpenter, G. (2001) · Science · doi:10.1126/science.1065412 · Cited by 856
Self-citationFrancis, R., McGrath, G., Zhang, J., Ruddy, D. A., Sym, M., Apfeld, J., Nicoll, M., Maxwell, M., Hai, B., Ellis, M. C., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00189-2 · Cited by 805
Cyclooxygenase‐independent actions of cyclooxygenase inhibitors
Tegeder, I., Pfeilschifter, J., & Geisslinger, G. (2001) · The FASEB Journal · doi:10.1096/fj.01-0390rev · Cited by 747
Haass, C., Lemere, C. A., Capell, A., Citron, M., Seubert, P., Schenk, D., Lannfelt, L., & Selkoe, D. J. (1995) · Nature Medicine · doi:10.1038/nm1295-1291 · Cited by 592
Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1
Esler, W. P., Kimberly, W. T., Ostaszewski, B. L., Diehl, T. S., Moore, C. L., Tsai, J.-Y., Rahmati, T., Xia, W., Selkoe, D. J., & Wolfe, M. S. (2000) · Nature Cell Biology · doi:10.1038/35017062 · Cited by 517
Sulindac Inhibits Activation of the NF-κB Pathway
Yamamoto, Y., Yin, M.-J., Lin, K.-M., & Gaynor, R. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.38.27307 · Cited by 494
A second cytotoxic proteolytic peptide derived from amyloid β-protein precursor
Lu, D. C., Rabizadeh, S., Chandra, S., Shayya, R. F., Ellerby, L. M., Ye, X., Salvesen, G. S., Koo, E. H., & Bredesen, D. E. (2000) · Nature Medicine · doi:10.1038/74656 · Cited by 395
Self-citationPodlisny, M. B., Ostaszewski, B. L., Squazzo, S. L., Koo, E. H., Rydell, R. E., Teplow, D. B., & Selkoe, D. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.16.9564 · Cited by 370
Self-citationCholesterol-Dependent γ-Secretase Activity in Buoyant Cholesterol-Rich Membrane Microdomains
Wahrle, S., Das, P., Nyborg, A. C., McLendon, C., Shoji, M., Kawarabayashi, T., Younkin, L. H., Younkin, S. G., & Golde, T. E. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0470 · Cited by 356
Self-citationPresenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors
Seiffert, D., Bradley, J. D., Rominger, C. M., Rominger, D. H., Yang, F., Meredith, J. E., Wang, Q., Roach, A. H., Thompson, L. A., Spitz, S. M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005430200 · Cited by 301
Nonsteroidal Anti-Inflammatory Drugs and Cancer Prevention
Baron, J. A., & Sandler, R. S. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.511 · Cited by 297
Lipoxygenase modulation to reverse carcinogenesis.
Shureiqi, I., & Lippman, S. M. (2001) · PubMed · Cited by 292
Xia, W., Zhang, J., Kholodenko, D., Citron, M., Podlisny, M. B., Teplow, D. B., Haass, C., Seubert, P., Koo, E. H., & Selkoe, D. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.12.7977 · Cited by 284
Self-citationThe role of Aβ42 in Alzheimer's disease
Younkin, S. G. (1998) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(98)80035-1 · Cited by 282
Golde, T. E., Eckman, C. B., & Younkin, S. G. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00043-0 · Cited by 244
Self-citationXia, W., Zhang, J., Perez, R., Koo, E. H., & Selkoe, D. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8208 · Cited by 238
Self-citationSoriano, S., Kang, D. E., Fu, M., Pestell, R., Chevallier, N., Zheng, H., & Koo, E. H. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.4.785 · Cited by 210
Self-citationTherapeutic strategies for Alzheimer's disease
Wolfe, M. S. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd938 · Cited by 190
γ-Secretase inhibitors repress thymocyte development
Hadland, B. K., Manley, N. R., Su, D.-M., Longmore, G. D., Moore, C. L., Wolfe, M. S., Schroeter, E. H., & Kopan, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131202798 · Cited by 187
Takahashi, Y., Hayashi, I., Tominari, Y., Rikimaru, K., Morohashi, Y., Kan, T., Natsugari, H., Fukuyama, T., Tomita, T., & Iwatsubo, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301619200 · Cited by 179
Petit, A., Bihel, F., da Costa, C. A., Pourquié, O., Checler, F., & Kraus, J.-L. (2001) · Nature Cell Biology · doi:10.1038/35074581 · Cited by 178
Alzheimer's disease: treatments in discovery and development
Citron, M. (2002) · Nature Neuroscience · doi:10.1038/nn940 · Cited by 165
Alzheimer disease therapy: Can the amyloid cascade be halted?
Golde, T. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17527 · Cited by 164
Self-citationLanz, T. A., Himes, C. S., Pallante, G., Adams, L., Yamazaki, S., Amore, B., & Merchant, K. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.048280 · Cited by 148
Selective inhibition of Aβ42 production by NSAID R‐enantiomers
Morihara, T., Chu, T., Ubeda, O. J., Beech, W. K., & Cole, G. M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01195.x · Cited by 138
Wiltfang, J., Av, S., Schnierstein, B., Kelemen, G., Matthies, U., Klafki, H., Staufenbiel, M., Huether, G., Rüther, E., & Kornhuber, J. (1997) · Electrophoresis · doi:10.1002/elps.1150180332 · Cited by 131
Weggen, S., Eriksen, J. L., Sagi, S. A., Pietrzik, C. U., Golde, T. E., & Koo, E. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304824200 · Cited by 129
Self-citationCell‐free assays for γ‐secretase activity
McLendon, C., Xin, T. A., Ziani‐Cherif, C., Murphy, M. P., Findlay, K. A., Lewis, P. A., Pinnix, I., Sambamurti, K., Wang, R., Fauq, A. H., et al. (2000) · The FASEB Journal · doi:10.1096/fj.00-0286fje · Cited by 114
Self-citationPerez, R. G., Squazzo, S. L., & Koo, E. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.9100 · Cited by 105
Self-citationPresenilin 1 Regulates Pharmacologically Distinct γ-Secretase Activities
Murphy, M. P., Uljon, S., Fraser, P. E., Fauq, A. H., Lookingbill, H. A., Findlay, K. A., Smith, T. E., Lewis, P. A., McLendon, D. C., Wang, R., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002812200 · Cited by 101
Self-citationBiochemical Characterization of the γ-Secretase Activity That Produces β-Amyloid Peptides
Zhang, L., Song, L., Terracina, G., Liu, Y., Pramanik, B., & Parker, E. M. (2001) · Biochemistry · doi:10.1021/bi0028800 · Cited by 93
Sagi, S. A., Weggen, S., Eriksen, J. L., Golde, T. E., & Koo, E. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303588200 · Cited by 78
Self-citationMoore, C. L., Leatherwood, D. D., Diehl, T. S., Selkoe, D. J., & Wolfe, M. S. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000100f · Cited by 63
Brooks, W. S., Kwok, J. B. J., Kril, J. J., Broe, G. A., Blumbergs, P. C., Tannenberg, A. E. G., Lamont, P. J., Hedges, P., & Schofield, P. R. (2003) · Brain · doi:10.1093/brain/awg084 · Cited by 62
Xia, W., Ostaszewski, B. L., Kimberly, W. T., Rahmati, T., Moore, C. L., Wolfe, M. S., & Selkoe, D. J. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0322 · Cited by 53
Aspartyl Protease Inhibitor Pepstatin Binds to the Presenilins of Alzheimer's Disease
Evin, G. M., Sharples, R. A., Weidemann, A., Reinhard, F. B. M., Carbone, V., Culvenor, J. G., Holsinger, R. M. D., Sernee, M. F., Beyreuther, K. T., & Masters, C. L. (2001) · Biochemistry · doi:10.1021/bi002770t · Cited by 43
Durkin, J. T., Murthy, S., Husten, E. J., Trusko, S. P., Savage, M. J., Rotella, D. P., Greenberg, B., & Siman, R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.29.20499 · Cited by 43
Strooper, B. D., & König, G. (2001) · Nature · doi:10.1038/35102656 · Cited by 38
The Search for γ-Secretase and Development of Inhibitors
Tsai, J.-Y., Wolfe, M. S., & Xia, W. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867023370185 · Cited by 37
Amyloid-lowering isocoumarins are not direct inhibitors of γ-secretase
Esler, W. P., Das, C., Campbell, W. A., Kimberly, W. T., Kornilova, A. Y., Diehl, T. S., Ye, W., Ostaszewski, B. L., Xia, W., Selkoe, D. J., et al. (2002) · Nature Cell Biology · doi:10.1038/ncb0502-e110b · Cited by 36
Okochi, M., Ishii, K., Usami, M., Sahara, N., Kametani, F., Tanaka, K., Fraser, P. E., Ikeda, M., Saunders, A. M., Hendriks, L., et al. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01378-1 · Cited by 33
Cited by
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 882
The secretases: enzymes with therapeutic potential in Alzheimer disease
De Strooper, B., Vassar, R., & Golde, T. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.218 · Cited by 799
Self-citationTherapeutics of Alzheimer's disease: Past, present and future
Anand, R., Gill, K. D., & Mahdi, A. A. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.004 · Cited by 747
Metadata
- Authors
- Weggen, S., Eriksen, J. L., Sagi, S. A., Pietrzik, C. U., Ozols, V., Fauq, A., Golde, T. E., & Koo, E. H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-08
- Volume
- 278
- Issue
- 34
- Pages
- 31831-31837
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2171469414
- Cited by
- 280
- References
- 56
- FWCI
- 13.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.